Linezolid: MAOI activity and potential drug interactions.
Hammerness
Paul
P
Parada
Hector
H
Abrams
Annah
A
D000081:Acetamides / Q000009:adverse effects*; D000293:Adolescent; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D002648:Child; D003863:Depression / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000523:psychology; D000069349:Linezolid; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D010019:Osteomyelitis / Q000188:drug therapy*; D023303:Oxazolidinones / Q000009:adverse effects*
D000081:Acetamides; D000890:Anti-Infective Agents; D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D008996:Monoamine Oxidase Inhibitors; D023303:Oxazolidinones; D008774:Methylphenidate; D000069349:Linezolid